Global Anthrax Vaccine Market Worth Over $22 Billion by 2034, Driven by Advanced Vaccine Developments and Rising Demand for Bioterrorism Defense
11 mars 2024 13h32 HE
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anthrax Vaccine Market by Vaccine Type, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
20 juil. 2023 18h03 HE
|
Emergent BioSolutions
Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use Authorization status, and will continue to work with the U.S....
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
24 juin 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License...
Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
30 juil. 2019 16h42 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its...
Global Biodefense Market To Reach USD 7.64 Billion By 2026 | Reports And Data
16 mai 2019 12h30 HE
|
Reports And Data
Supportive government initiatives in medical countermeasure preparedness against biological threats is a significant factor estimated to stimulate market demand. Market Size – USD 5.39 billion in...
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
19 mars 2019 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
28 déc. 2018 09h01 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration (FDA) for...
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
12 avr. 2018 06h30 HE
|
Emergent Biosolutions, Inc.
GAITHERSBURG, Md., April 12, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market...
Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 Billion
30 sept. 2016 09h04 HE
|
Emergent BioSolutions Inc.
GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a multi-year contract with the Biomedical Advanced Research and...